Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- POXEL.PA
- Price
- 0.55
- Stock movement down
- -0.02 (-3.35%)
- Company name
- Poxel SA
- Exchange
- (PA ,
- Currency
- EUR )
- Sector
- Healthcare >Biotechnology
- Market cap
- 29.24M
- Ent value
- 80.80M
- Price/Sales
- 11.37
- Price/Book
- -
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -
- 1 year return
- -16.05%
- 3 year return
- -34.62%
- 5 year return
- -42.78%
- 10 year return
- -27.74%
Last updated: 2025-04-12
DIVIDENDS
POXEL.PA does not pay dividends or no data was received
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 11.37 |
| Price to Book | - |
| EV to Sales | 31.42 |
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 53.26M |
| EPS (TTM) | -1.39 |
| FCF per share (TTM) | -0.72 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 2.57M |
| Gross profit (TTM) | -16.17M |
| Operating income (TTM) | -9.59M |
| Net income (TTM) | -44.24M |
| EPS (TTM) | -1.39 |
| EPS (1y forward) | - |
Margins
Loading...
Margins data
| Gross margin (TTM) | -628.62% |
| Operating margin (TTM) | -372.86% |
| Profit margin (TTM) | -1720.06% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 2.34M |
| Net receivables | 1.56M |
| Total current assets | 4.52M |
| Goodwill | 0.00 |
| Intangible assets | 10.00K |
| Property, plant and equipment | 2.70M |
| Total assets | 4.82M |
| Accounts payable | 1.21M |
| Short/Current long term debt | 47.03M |
| Total current liabilities | 13.29M |
| Total liabilities | 53.90M |
| Shareholder's equity | 0.00 |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -22.69M |
| Capital expenditures (TTM) | 14.00K |
| Free cash flow (TTM) | -22.70M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | - |
| Return on Assets | - |
| Return on Invested Capital | - |
| Cash Return on Invested Capital | - |
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 0.58 |
| Daily high | 0.59 |
| Daily low | 0.49 |
| Daily Volume | 2.30M |
| All-time high | 16.30 |
| 1y analyst estimate | 3.50 |
| Beta | 1.67 |
| EPS (TTM) | -1.39 |
| Dividend per share | - |
| Ex-div date | - |
| Next earnings date | - |
Downside potential
Loading...
Downside potential data
| POXEL.PA | S&P500 | |
| Current price drop from All-time high | -96.63% | -12.89% |
| Highest price drop | -99.24% | -56.47% |
| Date of highest drop | 13 Dec 2024 | 9 Mar 2009 |
| Avg drop from high | -65.33% | -11.07% |
| Avg time to new high | 869 days | 12 days |
| Max time to new high | 2304 days | 1805 days |
COMPANY DETAILS
Marketcap
29.24M
Marketcap category
Small-cap
Description
Poxel S.A., a clinical-stage biopharmaceutical company, develops novel treatments for metabolic diseases, type 2 diabetes, and liver diseases. The company's lead product is TWYMEEG (Imeglimin), an oral drug candidate that targets mitochondrial dysfunction and approved for the treatment of type 2 diabetes in Japan. It also develops PXL770, an adenosine monophosphate-activated protein kinase enzyme, which is in a Phase 2a clinical trial that treats chronic metabolic diseases, including diseases that affect the liver, such as non-alcoholic steatohepatitis (NASH); PXL065, an earlier stage programs that is in Phase 2 for the treatment of NASH focusing on chronic and rare metabolic indications. The company has a licensing agreement with Enyo Pharma S.A.S. for the development of farnesoid X receptor that is in Phase 2a study for the treatment of hepatitis B and NASH; and DeuteRx LLC for the development of PXL065, a mitochondrial dysfunction; and Sumitomo Pharma for development and commercialization of Imeglimin. Poxel S.A. was incorporated in 2009 and is headquartered in Lyon, France.
Employees
6
Website
Investor relations
-
SEC filings
CEO
Country
France
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
LYON, France, April 08, 2025--Regulatory News: POXEL SA (Euronext : POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with...
April 8, 2025
LYON, France, March 31, 2025--Regulatory News: POXEL SA (Euronext : POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with...
March 31, 2025
LYON, France, March 20, 2025--Regulatory News: POXEL SA (Euronext : POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with...
March 20, 2025
LYON, France, February 19, 2025--Regulatory News: POXEL SA (Euronext : POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases w...
February 19, 2025
LYON, France, February 11, 2025--Regulatory News: POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases wi...
February 11, 2025
LYON, France, January 31, 2025--Regulatory News: POXEL SA (Euronext : POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases wi...
January 31, 2025
LYON, France, January 23, 2025--Regulatory News: POXEL SA (Euronext : POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases wi...
January 23, 2025
LYON, France, January 21, 2025--Regulatory News: POXEL SA (Euronext : POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases wi...
January 21, 2025
LYON, France, January 20, 2025--Regulatory News: POXEL SA (Euronext : POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases wi...
January 20, 2025
LYON, France, January 20, 2025--Regulatory News: POXEL SA (Euronext : POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases wi...
January 20, 2025
Next page